How to change the leading site? | BradyKnows

Subscribe

The change of leading site is a major amendment, and the change application should be conducted.

Suggested Reading

GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests…
How should the evaluation of new items in the endpoint table be considered after the implementation of the new…
Do all medical devices require chemical characterization?
What factors may affect biocompatibility risk when using biological test data from similar devices for…
Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,…
What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can…
Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation?
For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation…
When combining subchronic and implantation tests in one project, what factors need to be considered, and how can…
How is the endotoxin limit for wound dressing products determined?
GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which…
Why is the extraction period typically 24 hours in China for cytotoxicity testing?

Previous: Does the sponsor of the clinical trial for the purpose of regulatory approval need to be consistent with the clinical trial approval, notice or filing and publication materials?

Next: Is it necessary to apply for changes in international cooperative scientific research activities that do not involve changes in the types, quantities and uses of human genetic resources?